Document Type : Original Article(s)


1 Assistant Professor, Cardiovascular Diseases Research Center AND Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

2 Cardiologist, Cardiovascular Diseases Research Center AND Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

3 General Practitioner, Cardiovascular Diseases Research Center AND Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran


BACKGROUND: In the clinical setting of patients with ST-elevation myocardial infarction (STEMI), there are controversies about the role of early heparin administration on the patients' outcome and the patency of the infarct-related artery (IRA). In this randomized clinical trial, we sought to investigate the effect of heparin administration time on the thrombolysis in myocardial infarction (TIMI) flow grade of patients with STEMI treated with primary percutaneous coronary intervention (PPCI).
METHODS: Eligible individuals were randomly assigned to two groups: early heparin administration (90 IU/kg) in the emergency department (group A, n = 92) and late heparin administration in the Cath lab (group B, n = 77). All demographic and clinical information and on admission examinations were documented. Clinical outcomes, 40-day mortality, and left ventricular (LV) function improvement in follow-up were also collected.
RESULTS: The mean age of patients was 57.1 ± 8.8 and 57.5 ± 7.5 years in groups A and B, respectively (P = 0.232). The history of hypertension (HTN) (34.8% vs. 53.2%, P = 0.016) and diabetes (14.1% vs. 29.9%, P = 0.013) was significantly lower in group A. The LV ejection fraction (LVEF) changes were significant before and after the intervention within each group. However, this change was not significantly different between the groups (P = 0.592). Post-intervention complications did not differ between the two groups (P > 0.05). In the proportion of cases with TIMI flow grade less than 2 in the IRA, no significant differences were observed between the groups. [P = 0.092 for left anterior descending (LAD) and P = 0.086 for left circumflex artery (LCX)].
CONCLUSION: Although heparin administration in patients with STEMI undergoing PPCI is safe and effective, the effect appears not to be time-dependent.


  1. Oldroyd KG, Zeymer U, et al. Economic evaluation of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: the CULPRIT-SHOCK trial. Eur J Health Econ 2020; 21(8): 1197-209.
  2. Timmis A, Townsend N, Gale C, Grobbee R, Maniadakis N, Flather M, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2017. Eur Heart J 2018; 39(7): 508-79.
  3. McGinley C, Mordi IR, Kell P, Currie P, Hutcheon S, Koch S, et al. Prehospital administration of unfractionated heparin in ST-segment elevation myocardial infarction is associated with improved long-term survival. J Cardiovasc Pharmacol 2020; 76(2): 159-63.
  4. Gershlick AH, Banning AP, Myat A, Verheugt FW, Gersh BJ. Reperfusion therapy for STEMI: Is there still a role for thrombolysis in the era of primary percutaneous coronary intervention? Lancet 2013; 382(9892): 624-32.
  5. Mirbolouk F, Salari A, Gholipour M, Nikfarjam S, Pourbahador R, Mohamadnia H, et al. The factors related to hospitalization period in patients with acute myocardial infarction treated after primary percutaneous coronary intervention. ARYA Atheroscler 2020; 16(3): 115-22.
  6. Vogel B, Claessen BE, Arnold SV, Chan D, Cohen DJ, Giannitsis E, et al. ST-segment elevation myocardial infarction. Nat Rev Dis Primers 2019; 5(1): 39.
  7. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review. JAMA 1997; 278(23): 2093-8.
  8. Sarkar A, Grigg WS, Lee JJ. TIMI Grade Flow. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2020.
  9. Brodie BR, Stone GW, Cox DA, Stuckey TD, Turco M, Tcheng JE, et al. Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. Am Heart J 2006; 151(6): 1231-8.
  10. Franchi F, Rollini F, Angiolillo DJ. Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol 2017; 14(6): 361-79.
  11. Giralt T, Ribas N, Freixa X, Sabate M, Caldentey G, Tizon-Marcos H, et al. Impact of pre-angioplasty antithrombotic therapy administration on coronary reperfusion in ST-segment elevation myocardial infarction: Does time matter? Int J Cardiol 2021; 325: 9-15.
  12. Gurbel PA, Tantry US. Percutaneous Coronary Intervention: Adjunctive Pharmacology. In: Myat A, Clarke S, Curzen N, Windecker S, Gurbel PA, editors. The Interventional Cardiology Training Manual.Cham: Springer International Publishing; 2018. p. 161-80.
  13. Bloom JE, Andrew E, Nehme Z, Dinh DT, Fernando H, Shi WY, et al. Pre-hospital heparin use for ST-elevation myocardial infarction is safe and improves angiographic outcomes. Eur Heart J Acute Cardiovasc Care 2021; 10(10): 1140-7.
  14. Sealy M, Stuart O, Ebbs P. Prehospital unfractionated heparin prior to primary PCI. Int Paramed Pract 2020; 10(3): 50-6.
  15. Liem A, Zijlstra F, Ottervanger JP, Hoorntje JC, Suryapranata H, de Boer MJ, et al. High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: The Heparin in Early Patency (HEAP) randomized trial. J Am Coll Cardiol 2000; 35(3): 600-4.
  16. Erlinge D, Omerovic E, Frobert O, Linder R, Danielewicz M, Hamid M, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med 2017; 377(12): 1132-42.
  17. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127(4): 529-55.
  18. Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA 2015; 313(13): 1336-46.
  19. Jollis JG, Al-Khalidi HR, Roettig ML, Berger PB, Corbett CC, Doerfler SM, et al. Impact of Regionalization of ST-Segment-Elevation Myocardial Infarction Care on Treatment Times and Outcomes for Emergency Medical Services-Transported Patients Presenting to Hospitals with Percutaneous Coronary Intervention: Mission: Lifeline Accelerator-2. Circulation 2018; 137(4): 376-87.
  20. Huber K, Goldstein P, Danchin N, Fox KA, Welsh R, Granger CB, et al. Enhancing the efficacy of delivering reperfusion therapy: a European and North American experience with ST-segment elevation myocardial infarction networks. Am Heart J 2013; 165(2): 123-32.
  21. Rodriguez-Leor O, Fernandez-Nofrerias E, Mauri J, Carrillo X, Salvatella N, Curos A, et al. Integration of a local into a regional primary angioplasty action plan (the Catalan Codi Infart network) reduces time to reperfusion. Int J Cardiol 2013; 168(4): 4354-7.
  22. Bidwell K. CRT-100.15 Heparin Administration in the Emergency Department for ST-Elevation Myocardial Infarction and Culprit Vessel Patency. JACC Cardiovasc Interv 2020; 13(4, Suppl): S5.
  23. Zamani B, Abdollahi A, Mardi A. The effect of heparin prescription before primary PCI on long-term and short-term clinical and para clinical results and the mortality of patients with acute coronary syndrome. Int J Basic Clin Pharmaco 2018; 7(4): 748-52.
  24. Chung WY, Han MJ, Cho YS, Kim KI, Chang HJ, Youn TJ, et al. Effects of the early administration of heparin in patients with ST-elevation myocardial infarction treated by primary angioplasty. Circ J 2007; 71(6): 862-7.